Vysis, Inc.

Nov 06, 01
10:40 ET	Vysis Reports Third Quarter 2001 Results
Oct 10, 01
07:00 ET	Vysis Again Named One of Chicagoland's Fastest Growing Technology Companies In Deloitte & Touche 'Fast 50' Program
Oct 08, 01
07:00 ET	Vysis to Exceed Third Quarter Earnings Expectations
Oct 04, 01
08:01 ET	Vysis Further Strengthens Intellectual Property Portfolio of Key Genomics Platforms
Sep 25, 01
08:01 ET	Vysis Obtains Exclusive License to Roche Intellectual Property and Technology For Fetal Cell Analysis
Aug 14, 01
08:03 ET	Vysis Reports Second Quarter 2001 Results
Aug 08, 01
08:01 ET	Vysis Files S-3 Registration Statement for A Secondary Public Offering Of Vysis Common Stock
Aug 02, 01
16:42 ET	Vysis, Inc. Announces Second Quarter 2001 Conference Call
08:01 ET	Vysis Receives FDA Clearance for UroVysion Bladder Recurrence Cancer Test
Jul 11, 01
11:25 ET	Vysis Majority Shareholder BP Files 13D Notice of Change of Investment Intention
Jul 10, 01
12:43 ET	Vysis Grants License to bioMerieux, Inc. Under Its Collins Patent
Jul 02, 01
08:30 ET	Vysis to Seek Appeal of Interim Ruling in Patent Infringement Suit; Firm Seeks Protection of Royalty Stream From Licensee
Jun 28, 01
07:01 ET	Vysis Signs Letter of Intent to Sell Food Testing Business to Neogen
May 23, 01
10:00 ET	Vysis, Inc. Invites You to Join Its Virtual CEO Summit Webcast
May 21, 01
10:00 ET	Vysis, Inc. Invites You to Join Its Virtual CEO Summit Webcast
May 09, 01
08:02 ET	Vysis Reports Solid First Quarter 2001 Financial Performance
May 02, 01
15:04 ET	Vysis, Inc. Announces First Quarter 2001 Conference Call
Apr 25, 01
07:55 ET	Vysis Announces a Cooperative Research and Development Agreement With The National Cancer Institute
Apr 23, 01
07:55 ET	Vysis Expands Scientific Advisory Board
Apr 18, 01
07:55 ET	Vysis Receives FDA Clearance for AneuVysion(R) Prenatal Test 510K Amendment Allowing Immediate Use of Test Results
Apr 02, 01
07:55 ET	Vysis Submits PathVysion(TM) HER-2 PMA Supplement to FDA Seeking Claim For Selecting Breast Cancer Patients for Herceptin(R) Therapy
Mar 01, 01
08:03 ET	Vysis Achieves Fourth Quarter Objective of Profitability
Feb 27, 01
11:50 ET	Vysis Elects Richard A. Lerner, M.D. as Director; Appointment Increases Board To Seven
Feb 22, 01
08:30 ET	Vysis, Inc. Announces Fourth Quarter 2000 Conference Call
Feb 08, 01
08:32 ET	Vysis Has Issued New U.S. Patent Covering Vysis' UroVysion(TM) Bladder Cancer Recurrence Assay
Jan 18, 01
08:05 ET	New U.S. Patent Strengthens Vysis' Genomic Microarray Position
Jan 11, 01
08:01 ET	American College of Medical Genetics and American Society of Human Genetics Publish Guidelines Endorsing Use of Fluorescence in Situ Hybridization (Fish) Tests for Prenatal Testing
Dec 14, 00
08:00 ET	Vysis and The Mayo Clinic Extend Research Collaboration To Develop New Genomic Tests for Bladder, Lung and Prostate Cancers
Dec 12, 00
07:29 ET	Vysis' HER-2 DNA Probe Test for Breast Cancer Cited in Journal of Clinical Oncology Article
Dec 07, 00
11:30 ET	Vysis' PathVysion(TM) HER-2 Test Selected as Patient Screening Method in Two Of the Largest-Ever Breast Cancer Clinical Trials
Dec 06, 00
08:01 ET	Vysis and Hoffman-La Roche to Collaborate on Use of Fish HER-2 Testing In Relation to Herceptin(R) Therapy
Dec 05, 00
09:03 ET	Vysis, Inc. Invites You to Join Its Virtual CEO Summit Webcast
Dec 01, 00
11:00 ET	Vysis, Inc. Invites You to Join Its Virtual CEO Summit Webcast
Nov 30, 00
08:30 ET	Vysis Submits FDA Application for First Genomic DNA-Probe Test For Monitoring Recurrence of Bladder Cancer
Nov 28, 00
08:00 ET	Vysis to Collaborate with European Company to Develop Automated Reading Of Its Genomic Tests
Nov 07, 00
08:31 ET	Vysis 3Q 2000 Operating Performance Approaches Profitability On 37 Percent Increase in Product Revenues; Breakeven Targeted for Fourth Quarter 2000
Oct 26, 00
08:32 ET	Research Study Presented At American Society Of Reproductive Medicine Reports Vysis' Patented CGH Technology Permits Analysis Of All Chromosomes For IVF Research
Oct 19, 00
18:11 ET	Vysis Named One of Greater Chicagoland's Fastest Growing Technology Companies in Deloitte & Touche "Fast 50" Program
Sep 28, 00
08:01 ET	Vysis Launches E-Commerce Capability for Genomic Disease Management Products
Aug 09, 00
08:00 ET	Vysis' Mid-Year Results on Target for Breakeven In Fourth Quarter 2000
Jul 20, 00
08:02 ET	Vysis Introduces DNA Probes to Detect IGH/BCL2 and Other IGH Gene Rearrangements
Jul 17, 00
09:00 ET	Vysis Receives Award for its Genomic Microarray Technology
Jun 07, 00
08:02 ET	Vysis Names John R. Sluis Senior Vice President and Chief Financial Officer
May 23, 00
08:03 ET	Vysis and Genentech to Collaborate On Use of Fish HER-2 Testing For Prescribing Herceptin(R) Therapy
May 02, 00
08:03 ET	Vysis Reports Substantial Progress in First Quarter
Mar 21, 00
08:31 ET	Vysis Reports Strategic Progress in 1999
Feb 29, 00
08:31 ET	Vysis Obtains French Registration of PathVysion(TM) DNA Probe Test for HER-2 Gene Amplification in Breast Cancer
Feb 24, 00
08:30 ET	Vysis Obtains Exclusive Rights to Yale European Fish Technology Patent
Feb 08, 00
08:30 ET	Vysis Sells French Distribution Subsidiary to Applied Genetic Services Ltd.
Feb 02, 00
08:32 ET	Vysis Elects Eileen A. Kamerick as Director; Appointment Increases Board to Six
Jan 31, 00
08:31 ET	Vysis Begins Shipments of Its GenoSensor(TM) Microarray System for Genomic Research
Jan 20, 00
08:30 ET	Vysis to Defend Patent Licensed to Gen-Probe
Jan 18, 00
08:30 ET	Expectant Mothers Say Vysis' 24-Hour Prenatal Chromosome Test Reduces Anxiety
Nov 15, 99
08:30 ET	Vysis Reports 1999 Improved Third Quarter Results
Nov 11, 99
08:35 ET	Vysis Resets Profitability Goal; More Streamlined, Focused Operations Expected To Reach Breakeven in 4Q 2000
Oct 19, 99
07:31 ET	Two Resign From Vysis Board
Sep 16, 99
08:30 ET	Study Reports 24-Hour Prenatal FISH Test 100% Accurate in the Management Of High-Risk Pregnancies
Sep 01, 99
08:01 ET	Gen-Probe, BP Amoco and Vysis Settle Pending Litigation
Aug 16, 99
09:20 ET	Vysis Reports 1999 Second Quarter Results
Jul 27, 99
13:20 ET	Vysis Acquires Intellectual Property of Aprogenex
Jul 22, 99
18:26 ET	Vysis Introduces Modular FISH Automation For High-Volume Testing
Jun 29, 99
09:36 ET	Vysis Announces Collaborative Research and Development Agreement With The National Institutes of Health and The Institute Of Pathology at The University Of Basel
Jun 16, 99
08:30 ET	Vysis and Eos Join Forces to Identify New Markers of Breast Cancer
May 17, 99
10:52 ET	Vysis Reports 1999 First Quarter Results
Mar 29, 99
16:38 ET	Vysis Announces Next Steps in Tightening Its Business Plan
16:30 ET	Vysis Reports 1998 Results
Jan 07, 99
08:25 ET	Leading Cancer Centers to Provide Vysis PathVysion(TM) Breast Cancer Test
08:25 ET	Vysis, Inc. Announces New Board Co-Chairmen and Independent Accountants
Dec 14, 98
08:15 ET	FDA Approves Vysis PathVysion Breast Cancer Test to Detect and Quantify HER-2 Gene
Nov 12, 98
08:02 ET	Vysis Announces Fiscal 1998 Third Quarter Results
Nov 10, 98
08:15 ET	FDA Advisory Committee Unanimously Recommends Approval of Vysis' Breast Cancer Test to Detect and Quantify HER-2 Gene
Oct 29, 98
08:02 ET	Vysis, Inc. to Market Automated FISH System
Oct 28, 98
08:31 ET	Vysis Introduces SpectraVysion System to Detect Hidden Chromosomal Abnormalities
Oct 27, 98
08:31 ET	Vysis Unveils First Commercial Genomic Array System for Detecting Abnormal Gene Numbers